A "Good" A1c in Advanced CKD with Recurrent Severe Hypoglycemia
A 71-year-old man with type 2 diabetes for 22 years (eGFR 27 mL/min/1.73 m², urine albumin-to-creatinine ratio 640 mg/g), heart failure with preserved ejection fraction, and mild cognitive impairment (MoCA 22) is referred after two falls in three months and an emergency visit for confusion at which point-of-care glucose was 51 mg/dL. He lives alone. Medications: metformin 500 mg twice daily, glipizide 10 mg twice daily, insulin glargine 22 units at bedtime, lisinopril, furosemide. HbA1c is 7.1%. Continuous glucose monitoring shows 14% of time below 70 mg/dL, 4% below 54 mg/dL, with a cluster between 2 and 4 a.m.; time in range is 58%. He reports no warning symptoms and says, "I feel fine - my numbers look great."
1. The HbA1c is 7.1%. Explain why this number cannot be trusted here and state the glycemic targets you would actually use.
Read the worked answer
Why the A1c misleads
- In advanced CKD, shortened red-cell survival, relative marrow suppression, iron and B12 deficiency, and carbamylation of hemoglobin all shift the A1c independently of glucose. The result can read falsely low or high; here it plainly does not match the CGM.
- The discordance is the point: a mean glucose consistent with 7.1% coexisting with 14% time below 70 mg/dL means glycemia is swinging widely, with postprandial peaks masking long nocturnal troughs. The A1c is blind to that variance, and variance is what is causing his falls.
- His hypoglycemia is also clinically silent - longstanding diabetes plus cognitive impairment has blunted his counterregulatory and symptomatic response, so the absence of warning symptoms is not reassurance.
Targets I would set
- Individualize away from tight control: 22 years of diabetes, established microvascular disease, CKD stage 4, cognitive impairment, and living alone. The legacy benefit of near-normoglycemia is essentially spent; the marginal harm of one more severe hypoglycemic event (fracture, arrhythmia, worsening cognition) dominates.
- HbA1c 7.5–8.0% as a rough anchor only, never as the primary endpoint.
- CGM-driven goals: time in range >50% (higher if achievable without hypoglycemia), time below 70 mg/dL <1%, time below 54 mg/dL essentially zero, and no nocturnal events.
- Review the CGM at every contact and treat any level 2 event as a treatment failure requiring regimen change, not education alone.
2. List what you would stop, reduce, or start at this visit, in order, and justify each decision in the context of his kidney function, heart failure, and cognition.
Read the worked answer
Stop, same day
- Glipizide. Sulfonylureas cause prolonged, often nocturnal hypoglycemia when GFR falls; the 2–4 a.m. cluster is the signature. Even glipizide, often called the "safer" sulfonylurea in CKD, is not safe in a man with documented level 2 events and no awareness. No taper needed.
- Metformin. eGFR 27 is below the accepted threshold of 30; continuation adds lactic-acidosis risk with negligible glycemic benefit at this GFR.
Reduce 3. Glargine 22 → ~14–16 units. Removing the sulfonylurea will push glucose up, so this is a deliberate partial reduction rather than a full stop, titrated against CGM fasting values with a target fasting glucose of roughly 110–150 mg/dL. Accept mild hyperglycemia for two weeks to break the hypoglycemia cycle.
Start or consider 4. Linagliptin is attractive: no renal dose adjustment, minimal hypoglycemia, weight neutral, once daily - good for a man with cognitive impairment and a pill-burden problem. 5. An SGLT2 inhibitor is defensible for his HFpEF, but initiation thresholds are agent-specific (~20–25 mL/min/1.73 m²) and glucose-lowering is minimal at eGFR 27. If started, pre-emptively reduce furosemide and monitor orthostasis, because falls are the presenting problem. 6. GLP-1 receptor agonist is reasonable if weight or postprandial excursions dominate, but only if he can tolerate GI effects and someone can support him. 7. Deprescribe or lower furosemide if there is any orthostatic component - the falls may be multifactorial.
3. His daughter asks whether he can still drive. Outline the safety plan and the metrics you would track over the next three months.
Read the worked answer
Driving
- A level 2 hypoglycemic event with confusion requiring outside assistance generally mandates a temporary driving prohibition - commonly one to three months depending on jurisdiction - and he should not drive until awareness and stability are documented, not merely until he "feels fine."
- Because he has impaired awareness, the standard is stricter: no driving until he has had no glucose <54 mg/dL for at least four weeks and has demonstrable recognition of lows, ideally corroborated by a companion.
Safety infrastructure
- CGM with a predictive low alert set high (e.g., 80 mg/dL) and an audible alarm he can hear; verify at a home visit, since a device he ignores is worse than none.
- Prescribe glucagon (nasal or autoinjector) and train both him and his daughter; confirm the prescription is filled.
- Written sick-day and missed-meal rules, carbohydrate sources in bedroom and car, and a check-in call system given he lives alone.
- Fall-risk review: orthostatic vitals, footwear, home hazards, medication count.
Metrics over three months
- CGM: time below 70 <1%, zero readings <54, zero nocturnal events, time in range >50%.
- Fall diary and any emergency visits; repeat MoCA at 3–6 months.
- Hypoglycemia awareness (Gold score) and confirmed CGM alarm use.
- A1c at three months only as a secondary check - the CGM and event history drive decisions.